Tavaglione Federica, De Vincentis Antonio, Jamialahmadi Oveis, Pujia Roberta, Spagnuolo Rocco, Picardi Antonio, Morano Susanna, Valenti Luca, Romeo Stefano, Vespasiani-Gentilucci Umberto
Clinical Medicine and Hepatology Unit, Department of Internal Medicine and Geriatrics, Campus Bio-Medico University, Rome, Italy.
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
JHEP Rep. 2021 Mar 2;3(3):100262. doi: 10.1016/j.jhepr.2021.100262. eCollection 2021 Jun.
BACKGROUND & AIMS: Type 2 diabetes is a major driver of fatty liver disease and its long-term complications. The aim of this study was to investigate the individual contribution of inborn and acquired risk factors for severe liver disease in individuals with type 2 diabetes from the UK Biobank study.
A total of 22,812 UK Biobank participants of European descent without clinical history of liver disease and liver cancer were prospectively followed for the development of severe liver disease, defined as a composite diagnosis of cirrhosis, decompensated liver disease, hepatocellular carcinoma, and/or liver transplantation from the National Health Service records. The contribution of inborn and acquired risk factors to the risk of incident severe liver disease was assessed by Cox proportional hazards models.
During a median follow-up of 8.9 years (IQR 8.1-9.6), there were 279 individuals with severe liver disease, including 255 with cirrhosis and/or decompensated liver disease, 47 with hepatocellular carcinoma, and 5 with liver transplantation; death from severe liver disease occurred in 83 individuals. Risk factors independently associated with increased risk of incident severe liver disease included abnormal aspartate aminotransferase (adjusted hazard ratio [aHR] 4.85, 95% CI 2.76-8.54), decrease in serum albumin (aHR 2.39, 95% CI 1.76-3.24) and platelet count (aHR 1.12, 95% CI 1.09-1.16), cardiovascular disease (aHR 1.86, 95% CI 1.23-2.79), microalbuminuria (aHR 1.55, 95% CI 1.04-2.30), rs738409 (aHR 1.67, 95% CI 1.27-2.18) and rs58542926 (aHR 1.63, 95% CI 1.12-2.39), while the net effect of male sex was protective (aHR 0.49, 95% CI 0.26-0.94).
These findings may help in clinical care to identify individuals with type 2 diabetes at risk of severe liver disease, in turn leading to personalised risk prediction and prevention strategies.
Type 2 diabetes is a key driver of severe liver disease, namely cirrhosis, hepatocellular carcinoma, and liver-related mortality. In Europeans with type 2 diabetes from the prospective UK Biobank study, abnormal liver function, cardiovascular disease, microalbuminuria, and genetic variants in and genes are the major independent risk factors for severe liver disease. These findings may contribute in clinical care to identify and closely monitor individuals with type 2 diabetes at risk of developing severe liver disease, requiring more intensive follow-up strategies.
2型糖尿病是脂肪肝疾病及其长期并发症的主要驱动因素。本研究旨在通过英国生物银行研究调查2型糖尿病患者中先天性和后天性危险因素对严重肝病的个体影响。
对总共22812名无肝病和肝癌临床病史的欧洲血统英国生物银行参与者进行前瞻性随访,以观察严重肝病的发生情况,严重肝病定义为根据国家医疗服务记录综合诊断为肝硬化、失代偿性肝病、肝细胞癌和/或肝移植。通过Cox比例风险模型评估先天性和后天性危险因素对新发严重肝病风险的影响。
在中位随访8.9年(四分位间距8.1 - 9.6年)期间,有279人患有严重肝病,包括255人患有肝硬化和/或失代偿性肝病、47人患有肝细胞癌和5人接受了肝移植;83人死于严重肝病。与新发严重肝病风险增加独立相关的危险因素包括天门冬氨酸氨基转移酶异常(调整后风险比[aHR] 4.85,95%置信区间[CI] 2.76 - 8.54)、血清白蛋白降低(aHR 2.39,95% CI 1.76 - 3.24)和血小板计数降低(aHR 1.12,95% CI 1.09 - 1.16)、心血管疾病(aHR 1.86,95% CI 1.23 - 2.79)、微量白蛋白尿(aHR 1.55,95% CI 1.04 - 2.30)、rs738409(aHR 1.67,95% CI 1.27 - 2.18)和rs58542926(aHR 1.63,95% CI 1.12 - 2.39),而男性的净效应具有保护作用(aHR 0.49,95% CI 0.26 - 0.94)。
这些发现可能有助于临床护理中识别有严重肝病风险的2型糖尿病患者,进而制定个性化的风险预测和预防策略。
2型糖尿病是严重肝病(即肝硬化、肝细胞癌和肝脏相关死亡率)的关键驱动因素。在前瞻性英国生物银行研究中患有2型糖尿病的欧洲人中肝功能异常、心血管疾病、微量白蛋白尿以及某些基因中的基因变异是严重肝病的主要独立危险因素。这些发现可能有助于临床护理中识别和密切监测有发生严重肝病风险的2型糖尿病患者,需要更强化的随访策略。